Viridian Therapeutics, Inc.\DE(VRDN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,588 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
VRDN Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Viridian Therapeutics, Inc.\DE (VRDN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VRDN at 27.2/100 on a 32-signal composite quality model, placing it at rank #2,588 of 2,961 stocks — the bottom half of the AI-ranked universe. VRDN scores in the top quartile across revenue growth (99.3). Areas of concern include free cash flow (2.8) and profitability (3.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Viridian Therapeutics, Inc.\DE reports quarterly revenue of $284.0K, net income of $-127.1M, free cash flow of $-106.6M. Top institutional holders of VRDN by reported 13-F value include FMR, BlackRock, Bellevue Group AG, based on the most recent SEC filings. VRDN trades on the Nasdaq exchange and files with the SEC under CIK 1590750. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VRDN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Viridian Therapeutics, Inc.\DE directly from SEC EDGAR. Viridian Therapeutics, Inc.\DE's 13F Pro composite quality score has ranged between 24 and 32 since 2026, currently 27.2 — an improving long-term trajectory across 48 quarterly and live scoring snapshots.
Revenue
Q2 2026
$284.0K
Net Income
Q2 2026
$-127.1M
Free Cash Flow
Q2 2026
$-106.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+23359.9% YoYNet Income
-26.9% YoYOperating Income
-21.5% YoYEPS (Diluted)
Total Assets
+21.1% YoYTotal Debt
Op. Cash Flow
-19.0% YoYFree Cash Flow
-18.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $70.8M +23359.9% | $302.0K -3.8% | $314.0K -82.3% | $1.8M -40.2% | $3.0M +182.2% | $1.1M |
| Net Income | $-342.6M -26.9% | $-269.9M -13.6% | $-237.7M -83.0% | $-129.9M -63.5% | $-79.4M +28.3% | $-110.7M |
| Operating Income | $-363.4M -21.5% | $-299.0M -17.5% | $-254.4M -89.5% | $-134.3M -68.5% | $-79.7M +27.8% | $-110.4M |
| EPS (Diluted) | — | — | $-5.31 -31.1% | $-4.05 +39.2% | $-6.66 +78.6% | $-31.13 |
| Total Assets | $899.4M +21.1% | $742.4M +51.4% | $490.4M +12.7% | $435.1M +113.6% | $203.7M +55.2% | $131.3M |
| Total Debt | — | $20.6M +1.9% | $20.2M +335.0% | $4.6M | $0.00 | — |
| Operating Cash Flow | $-276.4M -19.0% | $-232.3M -26.1% | $-184.2M -96.3% | $-93.8M -71.9% | $-54.6M -83.3% | $-29.8M |
| Free Cash Flow | $-276.9M -18.9% | $-232.8M -25.8% | $-185.1M -95.6% | $-94.6M -72.3% | $-54.9M -84.2% | $-29.8M |
Get alerted when VRDN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Viridian Therapeutics, Inc.\DE including:
Top Institutional Holders of VRDN
FMR LLC
$305.0M16,604,740 shBlackRock, Inc.
$157.1M8,551,488 shBellevue Group AG
$123.7M6,731,909 shParadigm Biocapital Advisors LP
$123.5M6,723,788 shKynam Capital Management, LP
$118.6M6,453,877 shSTATE STREET CORP
$112.5M6,124,976 shPRICE T ROWE ASSOCIATES INC /MD/
$105.6M5,748,410 shFairmount Funds Management LLC
$93.5M5,090,928 shVANGUARD CAPITAL MANAGEMENT LLC
$84.1M4,576,860 shDeep Track Capital, LP
$66.0M3,592,740 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $305.0M | 16,604,740 |
| BlackRock, Inc. | $157.1M | 8,551,488 |
| Bellevue Group AG | $123.7M | 6,731,909 |
| Paradigm Biocapital Advisors LP | $123.5M | 6,723,788 |
| Kynam Capital Management, LP | $118.6M | 6,453,877 |
| STATE STREET CORP | $112.5M | 6,124,976 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $105.6M | 5,748,410 |
| Fairmount Funds Management LLC | $93.5M | 5,090,928 |
| VANGUARD CAPITAL MANAGEMENT LLC | $84.1M | 4,576,860 |
| Deep Track Capital, LP | $66.0M | 3,592,740 |
Companies Similar to VRDN
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Kymera Therapeutics, Inc.
CYTOKINETICS INC
Tango Therapeutics, Inc.
AGIOS PHARMACEUTICALS, INC.
Syndax Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc.
Invivyd, Inc.
Immunocore Holdings plc
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put VRDN on your watchlist
Track score changes the day Viridian Therapeutics, Inc.\DE files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is VRDN a good stock to buy?
13F Pro's AI-powered analysis of Viridian Therapeutics, Inc.\DE (VRDN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VRDN are available on the VRDN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. VRDN is classified as a mid company.
Which hedge funds own VRDN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VRDN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Viridian Therapeutics, Inc.\DE's investment landscape.